SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-264980
Filing Date
2020-10-07
Accepted
2020-10-06 21:35:02
Documents
15
Period of Report
2020-10-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d24439d8k.htm   iXBRL 8-K 56239
2 EX-2.1 d24439dex21.htm EX-2.1 519112
3 EX-2.2 d24439dex22.htm EX-2.2 56065
4 EX-2.3 d24439dex23.htm EX-2.3 57037
  Complete submission text file 0001193125-20-264980.txt   976672

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eidx-20201005.xsd EX-101.SCH 3054
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20201005_lab.xml EX-101.LAB 18887
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20201005_pre.xml EX-101.PRE 11849
8 EXTRACTED XBRL INSTANCE DOCUMENT d24439d8k_htm.xml XML 3454
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38533 | Film No.: 201227968
SIC: 2834 Pharmaceutical Preparations